Displaying drugs 9926 - 9950 of 12143 in total
Camrelizumab
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Investigational
Matched Description: … ED-SCLC After Failure of First Line Standard Therapy). ... is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of …
RSV-604
RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Investigational
Matched Description: … Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.). ... is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of …
Foralumab
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Investigational
Matched Description: … Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab …
Tilsotolimod
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Investigational
Matched Description: … With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)). ... Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
XL784
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because ... Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers ... of its important role in blood vessel formation and cell proliferation. …
ARC183
ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and specificity. The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life,...
Investigational
Matched Description: … The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short ... ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that ... , giving it the potential to be an ideal agent for medical procedures that require rapid resolution of …
Sitimagene ceradenovec
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
Investigational
Matched Description: … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high ... grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy …
CRx-401
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of …
DTX-101
DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.
Investigational
Matched Description: … It was previously investigated for the treatment of hemophilia B; however, the clinical development of ... DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector …
MRx-4DP0004
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Investigational
Matched Description: … MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. ... It is a live biotherapeutic derived from the microbiota of a healthy human infant. …
M0002
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Matched Description: … profound diuresis without loss of electrolytes. ... It will be of major benefit to those patients not responding satisfactorily to diuretics alone. ... It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce …
LX201
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Matched Description: … to the eye over the course of one year. ... LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally ... LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) …
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … that promotes growth and production of blood platelets. ... SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor ... used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of …
Cellobiose
A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]
Experimental
Matched Description: … Obtained from the partial hydrolysis of cellulose. [PubChem] ... A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. …
Molidustat
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
Matched Description: … of Renal Anemia in Non-dialysis Subjects). ... Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction …
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Sisunatovir
Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Investigational
Matched Description: … Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of …
Opiranserin
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty). ... Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of …
Rilzabrutinib
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Matched Description: … for the treatment of immune disorders, such as immune thrombocytopenic purpura. ... Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated …
Lumicitabine
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
Matched Description: … Food on the Pharmacokinetics of the 2 New Concept Formulations). ... is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of ... Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of …
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Description: … activity against the coronavirus family of viruses. ... new virions, resulting in the accumulation of inactivating mutations. ... A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of …
Naftopidil
Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.
Investigational
Matched Description: … Naftopidil has been investigated for the treatment of Disorder of Urinary Stent. …
beta-Sitosterol
Active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity.
Experimental
Matched Description: … Active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. …
Displaying drugs 9926 - 9950 of 12143 in total